安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tenecteplase - StatPearls - NCBI Bookshelf
Tenecteplase is an FDA-approved medication specifically indicated for reducing mortality in patients with ST-elevation acute myocardial infarction (STEMI) Off-label indications include thrombolysis in treating acute ischemic stroke, pulmonary embolism, and central venous catheter clearance
- Acute Ischemic Stroke Treatment | TNKase® (tenecteplase)
Learn about TNKase® (tenecteplase) for the treatment of acute ischemic stroke (AIS) Please see full Prescribing Information for additional Important Safety Information
- Genentech: TNKase® (tenecteplase) - Information for Patients
Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions This can lead to degradation of fibrinogen in blood samples removed for analysis Inform patients that bleeding can occur 1 or more days after administration of TNKase
- Tenecteplase (TNK-tPA) • LITFL • CCC
Tenecteplase is a tissue plasminogen activator used as a thrombolytic medication in: Acute Ischaemic Strokes, Acute Myocardial Infarction, PE
- Tenecteplase Uses, Side Effects Warnings - Drugs. com
What is tenecteplase? Tenecteplase is a thrombolytic (THROM-bo-LIT-ik) drug, sometimes called a "clot-busting" drug It helps your body produce a substance that dissolves unwanted blood clots Tenecteplase is used to prevent death in people who have had a heart attack (acute myocardial infarction)
- Tenecteplase - Wikipedia
Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in
- TNKase® (Tenecteplase) - Food and Drug Administration
TNKase® (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI) Treatment should be initiated as soon as possible after the onset of
- Tenecteplase - STROKE MANUAL
tenecteplase (METALYSE) is a genetically modified form of tissue plasminogen activator (tPA) with increased resistance to PAI, greater fibrin specificity, and a longer half-life (17±7min), allowing for a single bolus administration
|
|
|